
Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials
Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More












